Analysts expect Inogen Inc (NASDAQ:INGN) to post $61.99 million in sales for the current fiscal quarter, Zacks Investment Research reports. Three analysts have provided estimates for Inogen’s earnings. The highest sales estimate is $62.20 million and the lowest is $61.67 million. Inogen posted sales of $50.85 million during the same quarter last year, which suggests a positive year over year growth rate of 21.9%. The company is expected to issue its next quarterly earnings results on Tuesday, February 27th.
According to Zacks, analysts expect that Inogen will report full-year sales of $61.99 million for the current year, with estimates ranging from $242.00 million to $247.80 million. For the next fiscal year, analysts expect that the firm will report sales of $297.72 million per share, with estimates ranging from $286.10 million to $304.27 million. Zacks Investment Research’s sales averages are an average based on a survey of research firms that cover Inogen.
Inogen (NASDAQ:INGN) last announced its quarterly earnings data on Tuesday, November 7th. The medical technology company reported $0.33 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.29 by $0.04. The firm had revenue of $69.00 million for the quarter, compared to the consensus estimate of $63.55 million. Inogen had a net margin of 11.36% and a return on equity of 13.37%. The business’s revenue for the quarter was up 26.8% on a year-over-year basis. During the same period in the prior year, the company posted $0.25 earnings per share.
A number of equities research analysts have recently weighed in on INGN shares. Needham & Company LLC raised their price target on shares of Inogen from $108.00 to $125.00 and gave the company a “strong-buy” rating in a research note on Wednesday, November 8th. Piper Jaffray Companies restated a “hold” rating and issued a $90.00 price target on shares of Inogen in a research note on Tuesday, September 12th. BidaskClub downgraded shares of Inogen from a “buy” rating to a “hold” rating in a research note on Tuesday, December 5th. Zacks Investment Research upgraded shares of Inogen from a “hold” rating to a “buy” rating and set a $131.00 price target on the stock in a research note on Thursday, November 9th. Finally, Leerink Swann restated an “outperform” rating and issued a $120.00 price target (up from $115.00) on shares of Inogen in a research note on Wednesday, November 8th. Four investment analysts have rated the stock with a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $103.14.
Shares of Inogen (NASDAQ INGN) opened at $119.85 on Friday. Inogen has a one year low of $62.69 and a one year high of $130.05. The stock has a market cap of $2,491.92, a PE ratio of 97.07, a price-to-earnings-growth ratio of 4.05 and a beta of 1.13.
In related news, Director Raymond Huggenberger sold 14,000 shares of the firm’s stock in a transaction that occurred on Monday, October 16th. The shares were sold at an average price of $94.07, for a total value of $1,316,980.00. Following the completion of the transaction, the director now owns 7,808 shares in the company, valued at approximately $734,498.56. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, EVP Byron Myers sold 35,000 shares of the firm’s stock in a transaction that occurred on Friday, November 17th. The shares were sold at an average price of $116.77, for a total transaction of $4,086,950.00. Following the completion of the transaction, the executive vice president now owns 48,600 shares of the company’s stock, valued at approximately $5,675,022. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 99,000 shares of company stock worth $10,926,345. 5.31% of the stock is currently owned by corporate insiders.
Hedge funds and other institutional investors have recently modified their holdings of the stock. Schroder Investment Management Group bought a new position in Inogen in the 2nd quarter valued at approximately $132,000. Ameritas Investment Partners Inc. raised its holdings in Inogen by 6.1% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 1,495 shares of the medical technology company’s stock valued at $143,000 after buying an additional 86 shares during the last quarter. Sei Investments Co. raised its holdings in Inogen by 38.1% in the 2nd quarter. Sei Investments Co. now owns 1,606 shares of the medical technology company’s stock valued at $153,000 after buying an additional 443 shares during the last quarter. Victory Capital Management Inc. raised its holdings in Inogen by 17.8% in the 2nd quarter. Victory Capital Management Inc. now owns 2,036 shares of the medical technology company’s stock valued at $194,000 after buying an additional 307 shares during the last quarter. Finally, Pinebridge Investments L.P. raised its holdings in Inogen by 1.6% in the 2nd quarter. Pinebridge Investments L.P. now owns 2,143 shares of the medical technology company’s stock valued at $204,000 after buying an additional 33 shares during the last quarter.
TRADEMARK VIOLATION WARNING: “Analysts Expect Inogen Inc (INGN) Will Announce Quarterly Sales of $61.99 Million” was first reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this piece of content on another website, it was illegally copied and reposted in violation of U.S. & international copyright legislation. The original version of this piece of content can be accessed at https://ledgergazette.com/2018/01/13/analysts-expect-inogen-inc-ingn-will-announce-quarterly-sales-of-61-99-million.html.
Inogen, Inc is a medical technology company. The Company develops, manufactures and markets portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The Company’s Inogen One systems concentrate the air around the patient to offer a single source of supplemental oxygen anytime, anywhere with a portable device.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Inogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen and related companies with MarketBeat.com's FREE daily email newsletter.